March 22, 2018 / 12:11 PM / 6 months ago

BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial

March 22 (Reuters) - Reata Pharmaceuticals Inc:

* REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL

* REATA PHARMACEUTICALS INC - RESULTS FROM PHASE 2 LARIAT TRIAL SHOWED SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT

* REATA PHARMACEUTICALS INC - NO SAFETY SIGNALS WERE IDENTIFIED IN TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below